MedPath

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center logo
🇺🇸United States
Ownership
Private
Established
1884-01-01
Employees
10K
Market Cap
-
Website
http://www.mskcc.org

Exercise Exposure Data Collection in Patients Undergoing Tumor Molecular Profiling

Active, not recruiting
Conditions
Carcinoma
Cancer
Interventions
Behavioral: Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire
First Posted Date
2017-07-05
Last Posted Date
2024-08-19
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
1600
Registration Number
NCT03208374
Locations
🇺🇸

Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States

and more 4 locations

PSMA PET Imaging of Recurrent Prostate Cancer

Phase 2
Active, not recruiting
Conditions
Prostate Adenocarcinoma
Prostate Cancer
Interventions
Drug: Ga-HBED-iPSMA PET
Diagnostic Test: PET/CT
Diagnostic Test: MRI
First Posted Date
2017-06-29
Last Posted Date
2024-07-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
1171
Registration Number
NCT03204123
Locations
🇺🇸

Memorial Sloan Kettering Nassau (Consent only), Uniondale, New York, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Consent only ), Montvale, New Jersey, United States

and more 4 locations

Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer

Not Applicable
Active, not recruiting
Conditions
Thyroid Cancer
Interventions
Procedure: PET Imaging
Other: 18F-tetrafluoroborate (18F-TFB)
First Posted Date
2017-06-22
Last Posted Date
2024-06-05
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
5
Registration Number
NCT03196518
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma

Phase 1
Withdrawn
Conditions
Solitary Bone Plasmacytoma
Interventions
Drug: Durvalumab
Radiation: Radiation therapy
First Posted Date
2017-06-22
Last Posted Date
2018-08-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT03196401
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Commack, Commack, New York, United States

🇺🇸

Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 3 locations

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Early Phase 1
Active, not recruiting
Conditions
Neuroblastoma (NB)
Interventions
First Posted Date
2017-06-16
Last Posted Date
2024-07-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
48
Registration Number
NCT03189706
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Acupuncture for Symptoms of Nerve Damage

Not Applicable
Completed
Conditions
Chemotherapy-induced Peripheral Neuropathy
Peripheral Neuropathy
Interventions
Procedure: Acupuncture
Procedure: Sham Acupuncture
Other: Usual Care Group
Behavioral: questionnaires
First Posted Date
2017-06-09
Last Posted Date
2024-05-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
75
Registration Number
NCT03183037
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Phase 2
Active, not recruiting
Conditions
Lymphoma
Relapsed
Refractory
Interventions
First Posted Date
2017-06-07
Last Posted Date
2024-08-14
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
47
Registration Number
NCT03179930
Locations
🇺🇸

Roswell Park Cancer Institute (Data Collection Only), Buffalo, New York, United States

🇺🇸

Memorial Sloan Kettering Westchester, Harrison, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 6 locations

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Phase 2
Active, not recruiting
Conditions
Hodgkin Lymphoma
Interventions
Drug: Pembrolizumab
Radiation: Involved Site Radiation Therapy
First Posted Date
2017-06-07
Last Posted Date
2024-12-05
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
22
Registration Number
NCT03179917
Locations
🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 6 locations

Ambulatory Cancer Care Electronic Symptom Self-Reporting for Surgical Patients

Completed
Conditions
Patient Reported Outcomes
Interventions
Other: Team Monitoring
Other: Enhanced Feedback
First Posted Date
2017-06-06
Last Posted Date
2023-06-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
2793
Registration Number
NCT03178045
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Phase 2
Completed
Conditions
Salivary Gland Cancer
Interventions
First Posted Date
2017-06-01
Last Posted Date
2024-12-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
64
Registration Number
NCT03172624
Locations
🇺🇸

Memorial Sloan Kettering Commack, Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States

🇺🇸

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath